Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

(4756)
•••

Comment by nozzpackon Dec 07, 2021 1:00pm

188 Views

Post# 34206923

RE:RE:Forecast EPS for 2021

Investing is forward looking although hind casting forms part of the DD.
One of those impairments was built into the share price and the other was optional but will remove a significant lability and benefit cash flows going forward and will look better in any buyout....which I think is the game plan here.

Biostent is a clone of CPH in almost every way...earnings, cash, revenues etc.
It trades at 21 times eps with a market cap of $110.

Value always emerges .

<< Previous

Bullboard Posts

Next >>

Tungsten and molybdenum for the US military and Elon Musk: Why Almonty's NASDAQ listing could provide the next boost